Clinical Trial Evidence for Wegovy Wegovy approval was supported by large, randomized clinical trials, including the STEP 1 study: 1,961 adults with obesity or overweight plus weight-related health conditions 68-week study duration Average weight loss of approximately 14.9% of body weight 86% of participants lost at least 5% of body weight 69% lost at least 10% 50% lost at least 15% Participants followed reduced-calorie diets and increased physical activity Before receiving FDA approval, GLP-1 medications completed Phase I, Phase II, and Phase III trials
In a Phase I clinical trial, the drug demonstrated positive preliminary effects, achieving an average weight reduction of over 8% after four weeks of treatment in an overweight or obese population, indicating its strong potential for weight loss
But buried in the legislation is something more consequential: mandatory safety data submission for self-affirmed GRAS ingredients
Options include ondansetron or prochlorperazine for short-term use
Verified customer Chris H This group of professionals are the best
.webp)
